Discover Algeria | About us | Press area | Contact | ||||||||
|
Les derniers textes juridiques
View more
Les interviews By AlgeriaInvest
Newsletter
NEW OPPORTUNITIES
NEW NEWS
November 14, 2024 | 2 months ago
Sharing
The Saidal Group is a key player in Algeria's pharmaceutical industry aiming for national self-sufficiency while positioning itself as a regional leader. It meets 70% of the national demand for medicines and aims to reach 100% within five years. Saidal also plans to export two-thirds of its production, targeting markets in Europe, India, and Africa.
Strategic axes:
-Increase local production:
-Launch 100 new medicines.
-Reduce cancer drug imports by $300 million with 27 oncology drugs by 2025.
Raw material
production:
Launch 9 active pharmaceutical ingredient manufacturing projects, including:
- Diabetes and cardiovascular medicines in
Batna.
- Paracetamol and aspirin in Batna.
-Cancer drugs in Sétif.
-Antibiotics in Médéa.
Innovation and export:
-Creation of a cell therapy laboratory and a specialised hospital.
-Partnership with the Karolinska Institute for the treatment of resistant
cancers.
-Development of vaccines with a world leader, including flu and paediatric
vaccines.
-Doubling exports, with medicines already registered in several African
countries.
New factories:
-Two factories in Mostaganem for ophthalmic and animal health products, potentially reducing imports by over $200 million.
Saidal aims to become a leading pharmaceutical company in Africa and the Middle East, contributing to import reduction and national economic development.
Sharing